Biocon Q1 FY27: PAT up 53% YoY at Rs 137 cr

Pat Growth 25pctExceptional ItemResults View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.7%Reaction day

₹425.20

prior close

₹428.00

announcement price

After-mkt

timing

Nifty Midcap 150market-0.4%+3.1% vs market

Pharmaceuticals peers, median of 167sector-0.2%+2.9% vs sector

On the reaction day the stock moved 3.1 pts more than Nifty Midcap 150 and 2.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-0.7

15m

-0.6

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.7-0.4+3.1-0.2+2.9

Next day

+0.3-0.2+0.5+0.4-0.1

+0.2+0.3-0.1+0.6-0.4

-0.2+0.2-0.5+0.7-1.0

+0.5+0.5+0.0+0.7-0.1

-1.2+0.6-1.8+1.0-2.2

-3.1+0.2-3.3-0.1-3.0

15d

-2.2+0.4-2.7+0.0-2.2

-7.9-1.5-6.5+2.5-10.4

-13.3-6.1-7.2+2.6-15.9

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon reported Q1 FY27 consolidated revenue of Rs 4,336 cr, up 10% YoY from Rs 3,942 cr. Net profit rose 53% to Rs 137 cr from Rs 89 cr. Biosimilars revenue grew 16% to Rs 2,856 cr. Standalone net profit was Rs 52 cr versus a loss of Rs 8 cr. BBL became wholly owned subsidiary on June 29, 2026. Board recommended Rs 0.50 final dividend per share. Exceptional items of Rs 13.5 cr booked.

Likely market impact

Strong PAT growth driven by Biosimilars; full BBL integration and dividend are positives; Services segment revenue declined 16%.